Bethesda-based Northwest Biotherapeutics (OTC: NWBO) released a statement to give surety to Investors that its DCVax drug, will not run into the same issues currently facing Seattle, Washington-based, Dendreon Corporation's (NASDAQ:DNDN) Provenge immune therapy drug.
